Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (clinicaltrials.gov) - Oct 14, 2026 - P1/2 | N=46 | Recruiting | Sponsor: Melanoma and Skin Cancer Trials Limited | Trial completion date: Jan 2026 ➔ Jan 2030 | Trial primary completion date: Jan 2026 ➔ Jan 2028
Checkpoint inhibition • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor
|